R&D tax relief for chemicals and materials companies

Where the science genuinely runs out

Qualifying work is where the outcome is not readily deducible by a competent professional. A novel formulation where component interaction, stability or performance cannot be predicted from existing knowledge and must be established experimentally, an appreciable improvement rather than a routine blend. New or appreciably improved material properties, strength, thermal or barrier performance, cure behaviour, in polymers, composites, coatings or adhesives. Reformulating to duplicate a product’s effect by a different route, such as removing a hazardous or restricted solvent, where matching the performance is technologically uncertain. And process chemistry and scale-up where plant-scale behaviour, heat and mass transfer, mixing, yield or impurity profile, creates genuine uncertainty that bench work did not resolve.

The work that feels like R&D but is not

The larger part of most chemicals businesses is routine. Formulation by established methods to a predictable result. Like-for-like substitution where the outcome is readily deducible. Cosmetic and aesthetic variants, a new colour, fragrance, flavour or pack size, with no underlying technological change. Applying a published recipe, a supplier formulation or a standard datasheet method. And routine quality control, analytical testing and batch release, which measure against a known standard rather than resolve uncertainty.

The consumables rule that bites hardest here

More than in most sectors, the consumables restriction shapes chemicals and materials claims. Reactants and materials transformed in genuine R&D can qualify, but where the item produced, or the product of the process, is sold or transferred in the ordinary course of business, the consumable cost incorporated into it is excluded. Because pilot and scale-up batches are so often saleable, this is where claims are most often overstated. The honest claim apportions: the proportion consumed in genuine R&D, net of what is sold, with discarded or scrapped trial output treated on its own terms.

Sector pitfalls we would check first

• Trial and error is not automatically R&D. Iteration qualifies only where it addresses a genuine uncertainty a competent professional could not readily resolve, not commercial recipe-tweaking.
• The scale-up boundary. R&D ends once a pilot process with the functional characteristics of the final process exists; routine production and optimisation that does not change the underlying technology is outside.
• Consumables sold in the ordinary course. The single most material restriction here, and the easiest to overclaim: apportion carefully. The rule is on qualifying costs.
• The overseas restriction. For periods from 1 April 2024, overseas contractor and worker costs are excluded unless the conditions genuinely cannot be replicated in the UK, which is read narrowly.

Sources

1. HMRC, Guidelines on the meaning of research and development for tax purposes (the DSIT Guidelines), gov.uk
2. HMRC, CIRD82300 (consumable or transformable items, and items sold), Corporate Intangibles Research and Development Manual, gov.uk